The review concerns modern pharmacological methods of Parkinson’s disease treatment. The basic drugs used in practice are levodopa, dopamine receptor agonists, MAO-B inhibitors, anticholinergics, СOMT inhibitors, and amantadine drugs. The article considers main features, assessment methods and targets of the differentiated therapy, presents benefits and drawbacks of each drug, and describes the problem of generics. According to the study, there is a preferences to use long-acting drugs. The choice of a drug for Parkinson’s disease treatment depends on such characteristics as the patient’s age, the character of Parkinson’s disease, the severity of movement disorder, concomitant diseases, the drug price, the patient’s individual sensitivity to different drugs. Finally, the article presents recommendations on initial treatment of Parkinson’s disease.
Parkinson’s disease, pharmacological therapy , dopamine
1. Artem’ev DV (2010). Parkinson’s disease treatment at a young age [Lechenie bolezni Parkinsona v molodom vozraste]. Nevrologiya, neyropsikhiatriya, psikhosomatika, (3), 6-11.
2. Artem’ev DV (2013). Rotigotine transdermal therapeutic system: new opportunities for Parkinson’s disease treatment [Rotigotin-transdermal’naya terapevticheskaya sistema: novye vozmozhnosti dlya lecheniya bolezni Parkinsona]. Sovremennaya terapiya v psikhiatrii i nevrologii, (1), 19-23.
3. Bykov YuN, Bender TB, Vasil’ev YuN (2015). Non-medication methods of rehabilitation in Parkinson’s disease [Nemedikamentoznye metody reabilitatsii pri bolezni Parkinsona]. Sibirskiy meditsinskiy zhurnal (Irkutsk), (6), 58-62.
4. Zakharov DV, Mikhaylov VA (2012). Experience of applying Rekquip Modutap in practice [Opyt primeneniya rekvipa modutaba v klinicheskoy praktike]. Nevrologiya, neyropsikhiatriya, psikhosomatika, (3), 60-62.
5. Illarioshkin SN (2015). Parkinson’s disease and the problem of generic drugs [Bolezn’ Parkinsona i problema dzhenerikov]. Nervnye bolezni, (1), 2-5.
6. Illarioshkin SN (2012). The capacity of dopamine receptor agonist pramipexole in Parkinson’s disease treatment [Vozmozhnosti agonista dofaminovykh retseptorov pramipeksola v lechenii patsientov s bolezn’yu Parkinsona]. Nevrologiya, neyropsikhiatriya, psikhosomatika, (2), 78-82.
7. Illarioshkin SN, Levin OS (2014). Parkinson’s disease and movement disorders [Bolezn’ Parkinsona i rasstroystva dvizheniya], 405.
8. Karabanov AV, Illarioshkin SN (2014). Experience of applying Mirapex ER in Parkinson’s disease [Opyt primeneniya mirapexa PD pri bolezni Parkinsona]. Nervnye bolezni, (3), 29-31.
9. Katunina EA (2010). Antioxidant therapy in the combination treatment of Parkinson’s disease [Antioksidantna terapiya v kompleksnom lechenii bolezni Parkinsona]. Russkiy meditsinskiy zhurnal, 18 (8), 470-488.
10. Levin OS (2013). Pramipexole in Parkinson’s disease treatment: practical aspects of application of extended release form [Pramipeksol v lechenii bolezni Parkinsona: prakticheskie aspekty primeneniya formy s zamedlennym vysvobozhdeniem]. Sovremennaya terapiya v psikhiatrii i nevrologii, (2), 24-29.
11. Levin OS (2013). How the Parkinson’s disease was treated in 2013 [Kak lechili bolezn’ Parkinsona v 2013 godu]. Sovremennaya terapiya v psikhiatrii i nevrologii, (3-4), 5-16.
12. Levin OS, Vasenina EE, Gan’kina OA (2015). Efficiency of Stalevo in the treatment of Parkinson’s disease with motor fluctuations (сlinical and pharmacoeconomic survey) [Effektivnost’ Stalevo v lechenii bol’nykh bolezn’yu Parkinsona s motornymi fluktuatsiyami (kliniko-farmoekonomicheskiy analiz)]. Sovremennaya terapiya v psikhiatrii i nevrologii, (1), 16-21.
13. Levin OS, Datieva VK (2013). Practical aspects of ropinirole with extended release (Requip Modutab) application in Parkinson’s disease treatment [Prakticheskie aspekty primeneniya ropinirola s dlitel’nym vysvobozhdeniem (rekvip modutab) v lechenii bolezni Parkinsona]. Nevrologiya, neyropsikhiatriya, psikhosomatica, (1), 46-49.
14. Levin OS, Datieva VK (2014). Tremor in Parkinson’s disease: peculiarities of phenomenology and treatment [Tremor pri bolezni Parkinsona: osobennosti fenomenologii i lecheniya]. Sovremennaya terapiya v psikhiatrii i nevrologii, (3), 14-19.
15. Levin OS, Fedorova NV (2012). Parkinson’s disease [Bolezn’ Parkinsona], 352.
16. Lyubimov AV, Chefranova ZhYu (2013). Medically induced disorders in Parkinson’s disease [Lekarstvenno-indutsirovannye rasstroystva pri bolezni Parkinsona]. Nauchnye vedomosti Belgorodskogo gosudarstvennogo universiteta. Seriya: Meditsina. Farmatsiya, 23 (18), 9-21.
17. Nodel’ MR (2013). Dopamine receptor agonist rotigotine efficiency in Parkinson’s disease treatment [Effektivnost’ agonista dofaminovykh retseptorov rotigotina v lechenii bolezni Parkinsona]. Nevrologiya, neyropsikhiatriya, psikhosomatika, (3), 60-63.
18. Obukhova AV (2014). Modern methods of Parkinson’s disease treatment [Sovremennaya terapiya bolezni Parkinsona]. Nevrologiya, neyropsikhiatriya, psikhosomatica, (3), 80-84.
19. Pyatikop VA, Maslovskiy CYu, Shchegel’skaya E (2011). The use of induced neural stromal stem autocells in Parkinson’s disease treatment [Ispol’zovanie neyroindutsirovannykh stromal’nykh stvolovykh autokletok v lechenii patsientov s bolezn’yu Parkinsona]. Mir meditsiny i biologii, 7 (2), 201-203.
20. Sayutina SB, Rozhkova NY (2014). Differentiated nootropic therapy in Parkinson’s disease and comorbide chronic cerebral ischemia [Differentsirovannaya nootropnaya terapiya pri bolezni Parkinsona i komorbidnoy khronicheskoy tserebral’noy ishemii]. Sibirskiy meditsinskiy zhurnal, 129 (6), 87-90.
21. Slobodin TN (2010). Neuroprotective effect of dopamine receptors agonists on the example of pramipexole in Parkinson’s disease treatment [Neyroprotektornoe deystvie agonistov dofaminovykh retseptorov na primere pramipeksola pri lechenii bol’nykh bolezn’yu Parkinsona]. Patologiya, 7 (2), 38-40.
22. Fedorova NV (2012). Extended-release pramipexole in Parkinson’s disease treatment [Prolongirovannyy pramipeksol v lechenii bolezni Parkinsona]. Nevrologiya, neyropsikhiatriya, psikhosomatica, (1), 112-115.
23. Fedotova SL, Bykov YuN (2014). Clinical and diagnostic characteristics of the vascular parkinsonism [Kliniko-diagnosticheskaya kharakteristika sosudistogo parkinsonizma]. Sibirskij medicinskij zhurnal (Irkutsk), (1), 24-27.
24. Shprakh VV, Sayutina SB (2010). Parkinson’s disease [Bolezn’ Parkinsona], 124.
25. Bonuccelli U (2003). Comparing dopamine agonists in Parkinson’s disease. Current Opinion in Neurology, 16 (3), 13-19.
26. Grill SE (2016). You ask. We answer: I’ve delayed taking levodopa for my Parkinson’s disease because I’m concerned about “off ” times, periods when the drug doesn’t work. Can you explain off times? Neurology Now, 12 (1), 27.
27. Gordon D (2011). An ounce of early intervention: Can early treatment of neurologic disorders such as multiple sclerosis and Parkinson’s disease slow disease progression? Neurology Now, 7 (2), 27-30.
28. Valeo T (2014). This way in: Parkinson’s with fewer side effects. Neurology Now, 10 (5), 7-12.
29. Zurowski M, O’Brien JD (2015). Developments in impulse control behaviours of Parkinson’s disease. Current Opinion in Neurology, 28 (4), 387-392.
